In-Hye Jung1, Si Yeol Song1, Jinhong Jung2, Byungchul Cho1, Jungwon Kwak1, Hyoung Uk Je3, Wonsik Choi4, Nuri Hyun Jung1, Su Ssan Kim1, Eun Kyung Choi1. 1. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 2. Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea. 3. Department of Radiation Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. 4. Department of Radiation Oncology, Gangneung Asan Hospital, Uiversity of Ulsan College of Medicine, Gangneung, Korea.
Abstract
PURPOSE: To evaluate the treatment results in early stage non-small cell lung cancer patients who have undergone fiducial-less CyberKnife radiosurgery (CKRS). MATERIALS AND METHODS: From June 2011 to November 2013, 58 patients underwent CKRS at Asan Medical Center for stage I lung cancer. After excluding 14 patients, we retrospectively reviewed the records of the remaining 44 patients. All analyses were performed using SPSS ver. 21. RESULTS: The median age at diagnosis was 75 years. Most patients had inoperable primary lung cancer with a poor pulmonary function test with comorbidity or old age. The clinical stage was IA in 30 patients (68.2%), IB in 14 (31.8%). The mean tumor size was 2.6 cm (range, 1.2 to 4.8 cm), and the tumor was smaller than 2 cm in 12 patients (27.3%). The radiation dose given was 48-60 Gy in 3-4 fractions. In a median follow-up of 23.1 months, local recurrence occurred in three patients (2-year local recurrence-free survival rate, 90.4%) and distant metastasis occurred in 13 patients. All patients tolerated the radiosurgery well, only two patients developing grade 3 dyspnea. The most common complications were radiation-induced fibrosis and pneumonitis. Eight patients died due to cancer progression. CONCLUSION: The results showed that fiducial-less CKRS shows comparable local tumor control and survival rates to those of LINAC-based SABR or CKRS with a fiducial marker. Thus, fiducial-less CKRS using Xsight lung tracking system can be effectively and safely performed for patients with medically inoperable stage I non-small cell lung cancer without any risk of procedure-related complication.
PURPOSE: To evaluate the treatment results in early stage non-small cell lung cancerpatients who have undergone fiducial-less CyberKnife radiosurgery (CKRS). MATERIALS AND METHODS: From June 2011 to November 2013, 58 patients underwent CKRS at Asan Medical Center for stage I lung cancer. After excluding 14 patients, we retrospectively reviewed the records of the remaining 44 patients. All analyses were performed using SPSS ver. 21. RESULTS: The median age at diagnosis was 75 years. Most patients had inoperable primary lung cancer with a poor pulmonary function test with comorbidity or old age. The clinical stage was IA in 30 patients (68.2%), IB in 14 (31.8%). The mean tumor size was 2.6 cm (range, 1.2 to 4.8 cm), and the tumor was smaller than 2 cm in 12 patients (27.3%). The radiation dose given was 48-60 Gy in 3-4 fractions. In a median follow-up of 23.1 months, local recurrence occurred in three patients (2-year local recurrence-free survival rate, 90.4%) and distant metastasis occurred in 13 patients. All patients tolerated the radiosurgery well, only two patients developing grade 3 dyspnea. The most common complications were radiation-induced fibrosis and pneumonitis. Eight patients died due to cancer progression. CONCLUSION: The results showed that fiducial-less CKRS shows comparable local tumor control and survival rates to those of LINAC-based SABR or CKRS with a fiducial marker. Thus, fiducial-less CKRS using Xsight lung tracking system can be effectively and safely performed for patients with medically inoperable stage I non-small cell lung cancer without any risk of procedure-related complication.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Noëlle C van der Voort van Zyp; Jean-Briac Prévost; Mischa S Hoogeman; John Praag; Bronno van der Holt; Peter C Levendag; Robertus J van Klaveren; Peter Pattynama; Joost J Nuyttens Journal: Radiother Oncol Date: 2009-03-16 Impact factor: 6.280
Authors: William T Brown; Xiaodong Wu; B-Chen Wen; John F Fowler; Fahed Fayad; Beatriz E Amendola; Silvio García; Alberto De La Zerda; Zhicong Huang; James G Schwade Journal: Comput Aided Surg Date: 2007-09
Authors: Oren B Factor; Charles C Vu; Jeffrey G Schneider; Matthew R Witten; Scott L Schubach; Alicia E Gittleman; Donna T Catell; Jonathan A Haas Journal: Front Oncol Date: 2014-10-20 Impact factor: 6.244
Authors: Christopher H Chapman; Christopher McGuinness; Alexander R Gottschalk; Sue S Yom; Adam A Garsa; Mekhail Anwar; Steve E Braunstein; Atchar Sudhyadhom; Paul Keall; Martina Descovich Journal: J Appl Clin Med Phys Date: 2018-04-26 Impact factor: 2.102
Authors: Rene Baumann; Mark K H Chan; Florian Pyschny; Susanne Stera; Bettina Malzkuhn; Stefan Wurster; Stefan Huttenlocher; Marcella Szücs; Detlef Imhoff; Christian Keller; Panagiotis Balermpas; Dirk Rades; Claus Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck Journal: Front Oncol Date: 2018-05-17 Impact factor: 6.244